LogicBio Therapeutics Inc (LOGC)

NASDAQ
2.070
0.000(0.00%)
  • Volume:
    0
  • Day's Range:
    2.060 - 2.070
  • 52 wk Range:
    0.257 - 3.440

LOGC Overview

Prev. Close
2.07
Day's Range
2.06-2.07
Revenue
10.76M
Open
2.06
52 wk Range
0.257-3.44
EPS
-0.805
Volume
0
Market Cap
68.23M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
523,714
P/E Ratio
-2.57
Beta
4.62
1-Year Change
-29.59%
Shares Outstanding
32,962,733
Next Earnings Date
Apr 03, 2023
What is your sentiment on LogicBio Therapeutics?
or
Market is currently closed. Voting is open during market hours.

LogicBio Therapeutics Inc News

LogicBio Therapeutics Inc Analysis

LogicBio Therapeutics Inc Company Profile

LogicBio Therapeutics Inc Company Profile

Employees
62

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsBuyBuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuySell
  • i do not know but 681% in Nasdaq?? ********
    1
    • rubbish
      0
      • lol
        0